scispace - formally typeset
C

Charles E. Hill

Researcher at Emory University

Publications -  74
Citations -  2309

Charles E. Hill is an academic researcher from Emory University. The author has contributed to research in topics: Warfarin & Medicine. The author has an hindex of 23, co-authored 65 publications receiving 2065 citations. Previous affiliations of Charles E. Hill include Medical University of South Carolina.

Papers
More filters
Journal ArticleDOI

Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor.

TL;DR: Investigating the histologic and immunohistochemical differentiation of Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) from other small, blue, round cell tumors found that FLI-1 protein expression is helpful in distinguishing ES/P NET from other tumors that may be CD99-positive, such as PDSS and RMS.
Journal ArticleDOI

Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients.

TL;DR: It is concluded that EBV-SMT are histologically distinct from classic soft tissue smooth muscle tumors, are not readily evaluated by means of conventional histologic criteria, and in the case of multifocal tumors are the result of multiple infection events rather than metastasis.
Journal ArticleDOI

The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States

Colleen S. Kraft, +261 more
TL;DR: While one patient experienced critical illness with multi-organ failure requiring mechanical ventilation and renal replacement therapy, both patients recovered without serious long-term sequelae to date.
Journal ArticleDOI

Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line

TL;DR: The results strongly implicate protein tyrosine phosphorylation as an event that mediates apoptosis and, thus, the antitumor activity of taxol in ovarian cancer.
Journal ArticleDOI

Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells

TL;DR: The data suggest that the effect of vemurafenib on the expression of immune system-relevant genes may depend on the zygosity of the BRAFV600E mutation, which is not routinely assessed in melanoma patients.